AIM: We evaluated the association between two medications that alter bioavailable androgen levels, finasteride and methadone, and risk of advanced HCV-related liver disease. BACKGROUND: Males have strikingly greater cirrhosis risk across disease etiologies, including hepatitis C virus (HCV) infection. METHODS: In a cross-sectional study in HCV+ male veterans, we determined medication use by up to 15-year medical record review, and hepatic pathology by the FibroSURE-ActiTest (F3/F4-F4, advanced vs. F0-F3, mild fibrosis; and A2/A3-A3, advanced vs. A0-A2, mild inflammation). We performed race-adjusted and race-stratified multivariate analyses. RESULTS: Among 571 HCV+ males, 43 % were White and 57 % African-American. There were non-significant decreased risks with finasteride use (OR(adj advanced fibrosis) = 0.75, 95 % CI 0.39-1.45 and OR(adj advanced inflammation) = 0.74, 95 % CI 0.41-1.43). For methadone, there was a non-significant 41 % increased advanced fibrosis risk in Whites and 51 % reduced risk in AA. White male methadone-users had 2.1-fold excess advanced inflammation risk (p = 0.15). CONCLUSIONS: Our preliminary study results suggest finasteride use is not significantly associated with a decreased risk of advanced hepatic fibrosis or inflammation in HCV+ males. The ethnically-divergent results for methadone associated fibrosis risk and finding of potentially increased inflammation risk in White males suggests the need for additional research.
AIM: We evaluated the association between two medications that alter bioavailable androgen levels, finasteride and methadone, and risk of advanced HCV-related liver disease. BACKGROUND: Males have strikingly greater cirrhosis risk across disease etiologies, including hepatitis C virus (HCV) infection. METHODS: In a cross-sectional study in HCV+ male veterans, we determined medication use by up to 15-year medical record review, and hepatic pathology by the FibroSURE-ActiTest (F3/F4-F4, advanced vs. F0-F3, mild fibrosis; and A2/A3-A3, advanced vs. A0-A2, mild inflammation). We performed race-adjusted and race-stratified multivariate analyses. RESULTS: Among 571 HCV+ males, 43 % were White and 57 % African-American. There were non-significant decreased risks with finasteride use (OR(adj advanced fibrosis) = 0.75, 95 % CI 0.39-1.45 and OR(adj advanced inflammation) = 0.74, 95 % CI 0.41-1.43). For methadone, there was a non-significant 41 % increased advanced fibrosis risk in Whites and 51 % reduced risk in AA. White male methadone-users had 2.1-fold excess advanced inflammation risk (p = 0.15). CONCLUSIONS: Our preliminary study results suggest finasteride use is not significantly associated with a decreased risk of advanced hepatic fibrosis or inflammation in HCV+ males. The ethnically-divergent results for methadone associated fibrosis risk and finding of potentially increased inflammation risk in White males suggests the need for additional research.
Authors: V Ratziu; P Giral; M Munteanu; D Messous; A Mercadier; M Bernard; R Morra; F Imbert-Bismut; E Bruckert; T Poynard Journal: Aliment Pharmacol Ther Date: 2007-01-15 Impact factor: 8.171
Authors: S A Kaplan; H L Holtgrewe; R Bruskewitz; B Saltzman; D Mobley; P Narayan; R H Lund; S Weiner; G Wells; T J Cook; A Meehan; J Waldstreicher Journal: Urology Date: 2001-06 Impact factor: 2.649
Authors: Gilles Morali; Yaacov Maor; Rachel Klar; Marius Braun; Ziv Ben Ari; Yoram Bujanover; Eli Zuckerman; Sarah Boger; Philippe Halfon Journal: Isr Med Assoc J Date: 2007-08 Impact factor: 0.892
Authors: Peter Bacchetti; Ross Boylan; Jacquie Astemborski; Hui Shen; Shruti H Mehta; David L Thomas; Norah A Terrault; Alexander Monto Journal: PLoS One Date: 2011-05-27 Impact factor: 3.240
Authors: Donna L White; Yanhong Liu; Jose Garcia; Hashem B El-Serag; Li Jiao; Spiridon Tsavachidis; Luis M Franco; Ju-Seog Lee; Shahriar Tavakoli-Tabasi; David Moore; Radoslav Goldman; Jill Kuzniarek; David J Ramsey; Fasiha Kanwal; Marco Marcelli Journal: Int J Mol Epidemiol Genet Date: 2014-10-22